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Malignantmesothelioma (MM) is an aggressivemalignancy of the serosal membranes. Early diagnosis and accurate prognostication
remain problematic. BAP1 is a tumour suppressor gene commonly mutated in MM. Germline BAP1 mutation has been associated
with early onset and less aggressive disease compared with sporadic MM. Sporadic BAP1mutations are common and are associated
with improved survival in MM, contrary to other malignancies. This study investigated the prognostic role of BAP1 in matched
cytology and surgical specimens and aimed to investigate the association between BAP1 and the established prognostic marker
VEGFA from a cohort of 81 patients. BAP1 mutation was found in 58% of histology and 59% of cytology specimens. Loss of
BAP1 expression in both surgical and cytology specimens was significantly associated with poorer survival in a multivariate
analysis when controlling for known prognostic indicators. Increased levels of VEGFA in pleural effusions were associated with
poor survival. We conclude that the prognostic significance of BAP1 mutations in MM cannot be determined in isolation of
other prognostic factors, which may vary between patients. Pathologists should employ caution when commenting on prognostic
implications of BAP1 status of MM patients in diagnostic pathology reports, but it may be useful for early diagnosis.
1. Introduction
Malignant mesothelioma (MM) is an aggressive malignancy
of the serosal membranes and is attributable in most cases
to prior asbestos exposure. Prognosis is currently poor, and
most deaths occur within 12–18 months of diagnosis, with
even shorter survivals on average for pleomorphic, sarcoma-
toid, and desmoplastic MMs. Most diagnoses occur at a late
stage, related to nonspecific symptoms and the long latency
period of the disease, and treatment response is limited.
Established prognostic indicators such as histological sub-
type, age, and gender can give some insight into predicting
patient survival [1–4]; however, there are few definitive and
specific prognostic indicators routinely used to predict likely
outcomes for individual patients. Previously identified addi-
tional prognostic indicators include levels of vascular
endothelial growth factor (VEGF), mesothelin and fibulin-3
in serum and pleural effusion, or expression of aquaporin-1
in tissue [5–10]; however, these are not routinely used in clin-
ical decision-making. Identification of robust prognostic
markers may allow for individualised patient management
regimens, with improved patient survival and quality of life.
The tumour suppressor gene BRCA-associated protein 1
(BAP1) is located at 3p21 and is commonly mutated in MM
tissue samples [11–17]. BAP1 is localised to the nucleus and
functions as a deubiquitinating enzyme, specifically regulat-
ing chromatin remodelling, functioning as a mediator of
DNA damage responses and growth suppression [18–20].
Recent evidence has shown that BAP1 plays a role in modu-
lation of calcium-induced apoptosis, and consequently muta-
tion may result in accumulation of DNA-damaged cells and
greater susceptibility to development of malignancy [21].
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Tumour suppressor gene function was previously thought to
be dependent on nuclear localisation; however, recent evi-
dence also suggests cytoplasmic activity [18, 21, 22]. Most
published mutations result in a truncated protein or mRNA
decay, and the site of the mutation has no known association
with the resulting cancer type [23, 24]. BAP1 knockdown
in vitro has resulted in decreased cell proliferation and medi-
ation of apoptosis in MSTO211H, HMeso, and H2373 meso-
thelioma cell lines, and reintroduction of wild-type BAP1 in
BAP1-null cell line NCI-H226 promoted cell growth, yet
another study reported that this was counterbalanced by
increased apoptosis, indicating that the consequences of
in vitro manipulation may be cell type dependent [11, 22].
Additionally, in vivo evidence in nude mice has shown that
injection of NCI-H226 (BAP1 negative) cells confers less
tumorigenicity when these cells are infected with lentivirus
carrying wild-type BAP1 compared to the mutated BAP1
[22], further indicating its role in tumour suppression. Muta-
tions of BAP1 may be sporadic or familial. Germline muta-
tions in BAP1 have been observed in families with a high
frequency of MM, associated with earlier age of onset, among
other malignancies such as uveal, ocular, and cutaneous mel-
anoma [16, 23, 25–27]. Given the high incidence of asbestos
exposure in previous decades, with incidence of MM still
rising in some nations, a better understanding of potential
predisposing genetic factors may provide insight into why
MM develops in only a minority of asbestos-exposed patients
and may allow identification of exposed persons at risk of
developing MM.
The molecular pathways of BAP1 in carcinogenesis are
not well understood, and it was previously suggested that
BAP1 interacted with BRCA-1; however, recent evidence
has contradicted this theory [28]. There is evidence of inter-
action with HCF-1 and subsequent regulation of cell prolifer-
ation at the level of the cell cycle G1/S checkpoint as well as
apoptosis regulation; however, the impact of upregulation
or downregulation of BAP1 is dependent on cell type [11,
22]. A number of associated mutations have been identified
as candidate genes in MM, particularly those involved with
regulation of hypoxia-inducible factor (HIF1α) and VEGF
[29–31]. HIF1α is regulated by VHL, which along with
BAP1 is commonly mutated in renal cell carcinoma and
located on the short arm of chromosome 3 [27]. Mutations
in VHL have been detected in MM samples [32], along with
other mutations at 3p21 such as SETD2 and PBRM1 [33].
Initially, acquired BAP1 mutation frequency in MM was
underestimated due to the use of Sanger sequencing and
NGS, which missed larger deletions [33, 34]. Consequently,
immunohistochemistry is thought to be the most reliable
method for detection of BAP1 mutation. Loss or mutation
of BAP1 can be visualised in most cases as undetectable
nuclear immunoreactivity in immunohistochemistry studies
[11]. Loss of BAP1 expression has been identified as an
adverse prognostic indicator in a number of different cancers
[35–38], potentially related to its role in tumour suppression.
In MM however, loss of BAP1 expression detected by immu-
nohistochemistry has shown contradictory prognostic impli-
cations, with some studies reporting improved patient
outcomes with loss of BAP1 expression, suggesting a
protective mechanism in disease development [14–16], and
others reporting no change in patient survival [39–41]. This,
in conjunction with germline data, signifies potential for its
involvement in disease pathogenesis.
This study recruited a cohort of MM patients diagnosed
at Flinders Medical Centre and established BAP1 status by
immunohistochemistry on matched surgical and cytology
specimens (i.e., samples were taken at the same time). We
aimed to evaluate any prognostic significance of BAP1 status
within this cohort, independent of established prognostic
indicators, in order to compare our findings with previous
contradictory data. This may provide further insight into
disease pathogenesis and allow for more specific prognostic
predictions in pathological analysis.
2. Methods
2.1. Patient Recruitment. A cohort of 83 patients was
recruited, diagnosed at the Department of Anatomical
Pathology at Flinders Medical Centre between the years
of 2006 to 2015. Archival tissue and cytology blocks were
available through SA Pathology. Patients were included on
the basis of histological diagnosis of MM, availability of
adequate tissue and cytology blocks, and clinical follow-
up information. Additionally, 18 cytology specimens from
patients presentingwithmalignant effusions due tometastatic
lung adenocarcinoma were also included to compare BAP1
expression between MM and adenocarcinoma, which may
be useful for differential diagnoses in selected cases. This work
was approved by the Southern Adelaide Clinical Human
Research Ethics Committee (approval number 381.09).
2.2. Pleural Effusion Specimen Collection. Pleural effusion
samples were obtained through SAPathology after processing
for diagnosis. Samples were spun at 500g for 5min, and the
supernatant was stored at −80°C immediately until further
use. Of this cohort, 18 samples were available for processing.
2.3. Immunohistochemical Analysis. Paraffin sections were
cut at 0.4 μm thick, then deparaffinised, and rehydrated in
graded concentrations of xylene and ethanol. Slides were
immersed in 3% H2O2 in 50% ethanol to quench endogenous
peroxidases. Heat-induced alkaline retrieval was performed
using Dako Target Retrieval Solution. Sections were blocked
with 10% normal goat serum in TBS for 30mins. Sections
were coated with 1 : 3000 mouse monoclonal BAP1 antibody
(Santa Cruz Biotechnology, Texas, USA, sc-28383) and were
incubated at 4°C overnight. The Novolink Max Polymer
Detection kit (Leica Biosystems, Nussloch, Germany) and
DAB+ Chromogen System (Dako Australia Pty. Ltd., NSW,
Australia) were used for detection, before haematoxylin
counterstaining. Diagnostic clinical procedures related to
diagnosis of the cases were performed in a NATA-approved
laboratory using QAP validated tests.
2.4. Histological Scoring. All slides underwent blinded
assessment by two RCPA-qualified pathologists, S.K. and
D.M. A positive result was defined as positive nuclear
labelling in any number of tumour cells, regardless of back-
ground cytoplasmic reactivity. Cytology specimens were
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excluded if cell count was not satisfactory (>20 malignant
cell/section required).
2.5. VEGFA ELISA. Levels of VEGFA, an established prog-
nostic factor in MM, were correlated with survival to assess
potential interaction of BAP1 and VEGFA. VEGFA levels
in pleural effusions were tested on the 17 patients for whom
effusion fluids were available. The VEGFA Duoset ELISA
(DY293B, R&D Systems) was used to detect VEGFA levels
as per kit instructions. Concentration was determined via
comparison to standard curves.
2.6. Statistical Analysis. Kappa scores were obtained to ana-
lyse agreement between pathologist opinions. Survival was
calculated as the number of months between diagnosis and
death of the patient, or last follow-up in the case of patients
still alive. If a patient was still alive at the last follow-up, sur-
vival was censored. Kaplan-Meier curves were implemented
to analyse survival, and Cox Regression univariate and mul-
tivariate analysis were used to evaluate covariates for statisti-
cal significance. A p value of <0.05 was deemed statistically
significant. Age, sex, and histological subtype were entered
into a multivariate model as they are universally accepted
prognostic factors in MM.
3. Results
3.1. Patient Characteristics. In total, 81 patients were eligible
for analysis of surgical sections, and 57 of these patients had
accompanying cytology sections for analysis. Table 1 sum-
marises the general patient characteristics for the entire
cohort. Mean survival was 10 months, and 98% of patients
were deceased at the conclusion of the study. Histological
subtype, age, sex, and chemotherapy are known prognostic
indicators in MM patients, with the epithelioid subtype gen-
erally having better survivals than sarcomatoid and biphasic
MMs. This was demonstrated in the multivariate analyses
of the surgical cohort, where the epithelioid subtype showed
a median overall survival of 11.2 months, significantly greater
than that of the sarcomatoid subtype (7.8 months, p = 0 015).
Chemotherapy and conservative therapy (pleurodesis and
palliative care) were the most common treatment options
but were not significant prognostic factors in univariate or
multivariate analysis. Age and sex had no statistical impact
on survival.
3.2. Immunohistochemistry. Positive nuclear immunoreac-
tivity in tumour cells of surgical and cytology specimens
was considered as retained BAP1 expression. Cytoplasmic
expression was disregarded. Agreement between pathologist
assessment (κ = 0 88) and surgical versus cytology BAP1 sta-
tus (κ = 0 85) for matched patients was analysed, both of
which indicated good agreement. BAP1 expression was lost
in 61% of epithelioid, 62% of biphasic, and 36% of sarcoma-
toid histology specimens (Table 2). Similarly, BAP1 expres-
sion was lost in 63% of epithelioid, 57% of biphasic, and
43% of sarcomatoid cytology specimens. Negative BAP1
labelling was observed in 62% of male and 44% of female
patient histology specimens and 65% of male and 36% of
female patient cytology specimens. However, we noted that
two earlier nontime-matched effusions for BAP1-negative
patients that at the time were diagnosed as reactive showed
loss of BAP1 when labelled retrospectively. None of the 18
metastatic lung adenocarcinomas showed loss of nuclear
labelling for BAP1.
3.3. BAP1 Prognostic Significance. BAP1 expression status
according to clinical data is summarised in Table 2. In uni-
variate analysis, loss of BAP1 expression in surgical sections
was significantly associated with poor survival within this
cohort (p = 0 014, Table 3). In the multivariate Cox regres-
sion model, loss of BAP1 expression in surgical and cytology
sections was significantly associated with poorer survival
(p = 0 003 and p = 0 04, resp., Table 4). For the surgical sec-
tions, median survival times were 6 months (95% CI, 4.3–
7.7 months) and 11 months (6.9–15.1 months) for negative
and positive BAP1 expression, respectively (Figure 1(a)).
Median survival times for cytology sections alone were 8
months (95% CI, 5.6–10.4 months) and 9 months (5.7–12.3
months) for negative and positive BAP1 expression, respec-
tively (Figure 1(b)). In epithelioid cases alone, BAP1 loss in
histology sections was associated with adverse prognostic
outcomes (p = 0 038); however, this was not evident in anal-
ysis of other subtypes or in the cytology group.
3.4. VEGFA Survival Validation. To further investigate prog-
nostic implications within our cohort and investigate the
potential role of BAP1 in regulating VEGFA levels, we
explored pleural effusion VEGFA protein concentrations
(Figure 2). Of this cohort, 6 BAP1-positive patients and 11
Table 1: Patient information.
Count (%)























BAP1-negative patients had pleural effusion supernatant
available for analysis. All those patients were diagnosed with
epithelioid MM. VEGFA levels were categorised into low
(<2000pg/mL) and high (≥2000 pg/mL) by previously estab-
lished cut-off values [6]. As expected, ELISA data showed
adverse prognostic outcomes for patients with high VEGFA
concentrations (p = 0 005). Median survival times were 13
(95% CI, 10–16.1 months) and 7 (95% CI, 5.8–8.1 months)
months for high and low VEGFA concentrations, respec-
tively. Of the 7 patients with high VEGFA levels, 6 showed
negative BAP1 expression.
4. Discussion
Regardless of conflicting evidence and theories on prognosti-
cation, it is evident that BAP1 is commonly mutated in MM
[11, 13, 14, 22]. Our data showed that BAP1-negative immu-
noreactivity was associated with poor survival in this cohort.
During immunohistochemical scoring, it was at times diffi-
cult to ascertain nuclear reactivity status, because the cell
populations often showed heterogeneity and background
cytoplasmic expression. This study used nuclear reactivity
as a marker for BAP1 expression. There is evidence for
BAP1 activity in the cytoplasm, and normal mesothelial cells
may show nuclear and weaker cytoplasmic labelling [21, 34];
but cytoplasmic labelling in isolation indicates mutated inac-
tive BAP1. Strong cytoplasmic labelling can be difficult to
interpret as it may spill over into the nucleus. For the pur-
poses of this study, we concentrated on the loss of nuclear
labelling, consistent with previous studies [13, 14, 17]. Malig-
nant cells can be difficult to distinguish from reactive meso-
thelial populations—especially problematic in effusion
fluids. These aspects resulted in some discrepancy between
the two pathologists. Conflicting slides were reviewed by
both pathologists separately, and all were independently
rescored as positive. While one other study reported a kappa
value of 1 [42], our study reports a value of 0.88 on initial
scoring. Although this value indicates good agreement, dis-
crepancies may result in variation of results between studies.
The inclusion criteria of this study required at least 20
cells to be present in a matched cytology specimen for this
analysis. Most cytology preparations suitable for analysis
are from patients with the epithelioid subtype, as sarcoma-
toid subtypes generally exhibit less shedding of cells into
the pleural space [43, 44]. In this cohort, 59% of MM patients
showed loss of BAP1 expression in cytology analysis, and a
kappa value of 0.85 between histology specimens and the
Table 2: BAP1 status in histology and cytology specimens.
BAP1 status
Surgical Cytology
Negative Positive Negative Positive
Total 47 (58%) 34 (42%) 34 (59%) 23 (41%)
Gender
Male 39 (62%) 24 (38%) 30 (65%) 16 (35%)
Female 8 (44%) 10 (56%) 4 (36%) 7 (64%)
Age
Median (range) 74 (53–92) 74 (35–91) 74 (53–92) 74 (35–91)
Subtype
Epithelioid 35 (61%) 22 (39%) 27 (63%) 16 (37%)
Biphasic 8 (62%) 5 (38%) 4 (57%) 3 (43%)
Sarcomatoid 4 (36%) 7 (64%) 3 (43%) 4 (57%)
Location
Pleural 47 (59%) 33 (41%) 34 (61%) 22 (39%)
Peritoneal 0 1 (100%) 0 1 (100%)
Table 3: Univariate analysis for prognostic indicators in MM.
Covariate p
Age (relative to median age of 74) 0.877
Sex 0.325
Subtype 0.134
BAP1 status (surgical) 0.014
BAP1 status (cytology) 0.205
Table 4: Multivariate analysis for prognostic indicators in MM.
Surgical Cytology
HR p HR p
Age
≤74 1.0 (ref) 1.0 (ref)
>74 1.369 0.214 1.778 0.070
Sex
Female 1.0 (ref) 1.0 (ref)
Male 1.3 0.376 1.701 0.378
Subtype
Epithelioid 1.0 (ref) 1.0 (ref)
Biphasic 2.565 0.081 2.585 0.052
Sarcomatoid 1.745 0.013 3.156 0.015
BAP1 status
<50% 2.226 0.003 1.882 0.047
>50% 1.0 (ref) 1.0 (ref)
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corresponding cytology specimens was reported. The three
cytology specimens that did not correlate with expression
in histology were all of epithelioid subtype and were scored
as positive contrary to the negative histology score. Due to
the difficulty in discriminating between reactive mesothelial
proliferations and the often scarce malignant cells in cytology
preparations, this is not a surprising result as interpretation is
dependent on the cell population present in that particular
section. It is possible that surface reactive cells were shed or
cells that may have corresponded to what is recognised as
in situ MM. Cytology analysis in isolation can yield confident
diagnosis of MM in conjunction with radiology and clinical
information, but in the absence of histology confirmation
or clinical radiological data, samples are often classified as
atypical or reactive mesothelial proliferations. Sensitivity of
cytology alone in diagnosis of MM is variable and dependent
on subtype, with one study reporting 53% sensitivity in the
epithelioid subtype compared to 20% sensitivity in sarcoma-
toid subtypes [45], and another reporting a sensitivity as low
as 27% but a specificity of 100% regardless of subtype [46].
Nonetheless, in practice, the diagnosis is not made in isola-
tion but always in conjunction with clinical and radiological
data, and/or a concurrent or subsequent biopsy. Due to the
implications of BAP1 in malignancy, where loss seems to be
exclusively seen in malignant lesions and despite the lack of
clarity in regard to its role in MM pathogenesis, BAP1 immu-
nohistochemistry on cytology preparations could potentially
be used as a specific screening marker for malignant versus
reactive pleural effusions, although retained nuclear labelling
does not exclude a MM, limiting sensitivity for diagnosis of
malignancy. Some of the patients recruited in this study
were admitted for pleural effusion drainage long before
MM was detected, and thus, this noninvasive procedure
may be useful for early flagging of these patients for
follow-up. One such patient is depicted in Figure 3. When
the first pleural effusion was drained, it contained only
scant mesothelial cells in an inflammatory background,
not considered suspicious at the time. Eight months later,
a more cellular pleural effusion was drained which con-
tained morular clusters and some papillary clusters of
atypical mesothelial cells, and the features were reported
as an atypical mesothelial proliferation. BAP1 was negative
on that cytology sample, and a concurrent pleural biopsy
showed noninvasive papillary atypical mesothelial prolifer-
ation, also BAP1 negative and in keeping with mesotheli-
oma in situ. Immunohistochemistry performed on the
first pleural effusion in retrospect showed loss of BAP1
at that time; had BAP1 labelling been performed In addi-
tion, since none of the metastatic lung adenocarcinomas
showed loss of nuclear labelling for BAP1, loss of nuclear
labelling may be an additional indicator supporting a diag-
nosis of mesothelioma.
The current study used immunohistochemistry for detec-
tion of mutation, in the absence of sequencing and/or qPCR,
but this may not detect all BAP1 mutations, as reported by us













































BAP1 status: cytology specimens
(b)
Figure 1: Kaplan-Meier curves for BAP1 expression in patient cohort. Retained nuclear expression in surgical sections was associated with
increased survival times (a). Median survival was 6 months (n = 47) and 11 months (n = 34) for negative and positive BAP1 expression,
respectively (p = 0 015). BAP1 expression in cytology sections was not significantly associated with prognosis (b). Median survival was 8
months (n = 33) and 9 months (n = 23) for negative and positive BAP1 expression, respectively (p = 0 205).
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in the case of uveal melanoma alone [48], where loss of
heterogeneity did not result in loss of BAP1 protein
expression. In addition, it has been proposed that miRNA
silencing of wild-type BAP1 may occur in heterogeneous
mutation, which may not be detected by immunohisto-
chemistry. One study has reported BAP1 loss by immuno-
histochemistry in the presence of normal BAP1 mRNA
levels, suggesting posttranslational modification or poten-
tial miRNA silencing of BAP1 [11]. However, overall
immunohistochemistry has emerged as a robust tool in
this context [34].
VEGFA prognostic data was utilised in this study for two
reasons: firstly, it is a previously established adverse prognos-
tic marker when elevated in pleural effusion, and secondly, it
is used to investigate the possible functional relationship
between BAP1 and VEGFA. Pleural effusions were available
for 18 of the recruited patients and were tested in order to
validate the role of VEGFA in this cohort, to confirm that
our cohort conforms to validated prognostic indicators, and
to explore any association between VEGFA, BAP1 status,
and survival. As expected, increased VEGFA levels were asso-
ciated with adverse prognosis in this cohort, and 7 of the 8
patients with high VEGFA levels were BAP1 negative. The
prognostication of MM may be more meaningful when a
number of markers are used in conjunction. While there
has been limited evidence of a link between molecular path-
ways, BAP1 mutation has coincided with VHL mutation in
clear cell renal cell carcinoma (ccRCC) [49]. VHL mutation
has been documented in MM previously; however, it is esti-
mated that VHL mutation is often underestimated due to
epigenetic regulation [32, 50]. It has been proposed that
BAP1 plays a role in sensitisation of drugs that target epige-
netic regulators such as histone deacetylases (HDACs) and
inhibitors of enhancer of zeste homolog 2 (EZH2) [51, 52].
Recent evidence reports that transient BAP1 mutation
increases the sensitivity of MM cell lines to HDAC inhibitors,
as opposed to long-term BAP1 loss where adaptation had
reduced sensitivity [51]. An inhibitor of HDAC has been
used in MM with little benefit, perhaps due to disregarding
BAP1 status [53]. In addition, HDAC inhibitors are impli-
cated in VEGFA regulation, and there may be possible func-
tional indirect role for BAP1 in this context. [54, 55]. A more
refined understanding of molecular pathways involving the
regulatory actions of BAP1 is required to elucidate potential
interactions between molecules. The use of BAP1 in conjunc-
tion with other prognostic indicators may be more clinically
useful than its use in isolation.
Our study differs from others by the higher proportion of
biphasic and sarcomatoid subtypes in our cohort. In addition,
our cohort has a higher mean age at diagnosis in comparison
to many studies, which may indicate acquired BAP1 muta-
tion in comparison to germline mutations. Germline muta-
tions are associated with earlier onset of disease, as opposed












































Figure 2: High VEGFA levels are associated with poor survival in a subsection of this cohort. All patients were diagnosed with epithelioid
MM. VEGFA levels were categorised into low (<2000 pg/mL) and high (≥2000 pg/mL). Adverse prognostic outcomes for patients
with high VEGFA concentrations were confirmed in this cohort (p = 0 005) with median survival of 13 (95% CI, 10–16.1 months) and
7 (95% CI, 5.8–8.1 months) months for high and low VEGFA concentrations, respectively (a). Of the 7 patients with high VEGFA levels,
6 showed negative BAP1 expression (b).
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of age, but were also associated with improved prognosis
[16, 25, 56]. Therefore, the patients in the present cohort
may exhibit shorter survival times than those diagnosed at
an earlier age. The mechanism of MM development in
patients with germline BAP1 mutation is unknown, but it
has been suggested that BAP1 mutation predisposes to aug-
mented sensitivity to asbestos-mediated carcinogenicity




Figure 3: BAP1 immunohistochemistry. A patient presented with a pleural effusion that contained only scant mesothelial cells in an
inflammatory background (a), diagnosed as reactive at the time. Only a few cells were seen in the cell block, but when this was labelled
retrospectively for BAP 1, there was no labelling (b). Eight months later, cellular pleural effusion was drained from the same patient which
contained papillary clusters of atypical mesothelial cells positive for calretinin (c) and showing loss of labelling for BAP1 (d). A diagnosis
of atypical mesothelial proliferation was rendered. A concurrent pleural biopsy showed noninvasive papillary atypical mesothelial
proliferation (e), also BAP1 negative (f) and in keeping with mesothelioma in situ.
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may include some unusual cases more difficult to diagnose
than most encountered in everyday practice, which again
may be associated with shorter survival times. A higher pro-
portion of BAP1 loss was seen in epithelioid cases, consistent
with previous studies [14, 17]. Patients diagnosed with epi-
thelioid MM generally have a better prognosis than those
diagnosed with biphasic and sarcomatoid cases [7], consis-
tent with the present cohort where epithelioid subtype was
significantly associated with improved outcomes compared
to the sarcomatoid subtype in multivariate analysis. If a
higher proportion of BAP1 loss occurs in the epithelioid
cases, it may skew the results when not controlled for sub-
type. Biphasic MMs consist of both epithelioid and sarcoma-
toid cell proliferations, and of the 13 biphasic cases included
in this study, one sample demonstrated heterogeneity in
BAP1 labelling between the two cell types with the less pre-
dominant sarcomatoid cell type retaining BAP1 expression
within the sample. A previous study reported loss of expres-
sion in both cell types, but with small areas of BAP1-positive
spindle-like cells, and proposed that BAP1 labelling could be
used to differentiate between biphasic cell populations and
epithelioid populations with reactive spindled epithelioid
cells for more accurate subtyping [17].
It is clear that although a number of genes have been sug-
gested as driver mutations in MM, a single-target approach
for therapy may not be the answer. Although BAP1 has been
described as a common mutation in MM cases, it is unlikely
that this will offer any therapeutic target due to the high
mutational load with heterogeneity of genetic changes in
MM cases, with resulting treatment resistance. We suggest
that care must be taken when interpreting BAP1 status in
diagnostic pathology reports and relating BAP1 status to
prognosis in isolation. A combination of established prog-
nostic markers could be used to assist in more accurate indi-
vidual prognostication. At this stage, histology analysis is
optimal for the clinical diagnosis of MM, but we hypothesise
that the use of BAP1 on cytology samples may become useful
in detecting malignancy at an earlier stage. The targeted
investigation of patients with multiple previous effusions or
clinical suspicion before surgical biopsy may permit earlier
diagnosis of MM and may provide some further uses for
BAP1 as a marker of malignancy. Further investigation of
the functional relationship with VEGFA status may provide
further insight into pathogenesis.
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